These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8075780)

  • 1. Treatment of Graves' disease by carbimazole: high dose with thyroxine compared to titration dose.
    Edmonds CJ; Tellez M
    Eur J Endocrinol; 1994 Aug; 131(2):120-4. PubMed ID: 8075780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized trial of short-term treatment of Graves' disease with high-dose carbimazole plus thyroxine versus low-dose carbimazole.
    Grebe SK; Feek CM; Ford HC; Fagerström JN; Cordwell DP; Delahunt JW; Toomath RJ
    Clin Endocrinol (Oxf); 1998 May; 48(5):585-92. PubMed ID: 9666870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug.
    McIver B; Rae P; Beckett G; Wilkinson E; Gold A; Toft A
    N Engl J Med; 1996 Jan; 334(4):220-4. PubMed ID: 8531998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of serum thyrotropin with thyroxine in patients with Graves' disease: effects on recurrence of hyperthyroidism and thyroid volume.
    Pfeilschifter J; Ziegler R
    Eur J Endocrinol; 1997 Jan; 136(1):81-6. PubMed ID: 9037131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical therapy of Graves' disease: does thyroxine prevent recurrence of hyperthyroidism?
    Lucas A; Salinas I; Rius F; Pizarro E; Granada ML; Foz M; Sanmartí A
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2410-3. PubMed ID: 9253309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of remission in Graves' disease treated with long-term carbimazole therapy: evaluation of technetium-99m thyroid uptake and TSH concentrations as prognostic indicators.
    Prakash R
    Eur J Nucl Med; 1996 Feb; 23(2):118-22. PubMed ID: 8925844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of remission after antithyroid drug treatment in Graves' disease.
    Young ET; Steel NR; Taylor JJ; Stephenson AM; Stratton A; Holcombe M; Kendall-Taylor P
    Q J Med; 1988 Feb; 66(250):175-89. PubMed ID: 2902655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.
    Maugendre D; Massart C
    Clin Endocrinol (Oxf); 2001 Jan; 54(1):89-96. PubMed ID: 11167931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of outcome in Graves' disease after carbimazole treatment.
    Weetman AP; Ratanachaiyavong S; Middleton GW; Love W; John R; Owen GM; Darke C; Lazarus JH; Hall R; McGregor AM
    Q J Med; 1986 Apr; 59(228):409-19. PubMed ID: 2875484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimum duration of antithyroid drug treatment determined by assay of thyroid stimulating antibody in patients with Graves' disease.
    Edan G; Massart C; Hody B; Poirier JY; Lé Reun M; Hespel JP; Leclech G; Simon M
    BMJ; 1989 Feb; 298(6670):359-61. PubMed ID: 2564286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy.
    Sabri O; Zimny M; Schreckenberger M; Reinartz P; Ostwald E; Buell U
    Thyroid; 1999 Dec; 9(12):1181-8. PubMed ID: 10646656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thyroid stimulating immunoglobulin bioactivity during carbimazole therapy as measured by the cytochemical bioassay.
    Prentice MG; Rayman GA; Alaghband-Zadeh J; Wise PH
    J Endocrinol Invest; 1987 Oct; 10(5):483-9. PubMed ID: 2892877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single daily dose short term carbimazole therapy for hyperthyroid Graves' disease.
    MacFarlane IA; Davies D; Longson D; Shalet SM; Beardwell CG
    Clin Endocrinol (Oxf); 1983 Jun; 18(6):557-61. PubMed ID: 6411390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Recurrence of Graves-Basedow disease: the influence of treatment schedule].
    Goñi Iriarte MJ; Forga Llenas L; Iriarte Beroiz A; Apiñániz EA; Rodríguez Erdozain R; Menéndez Torre E
    Med Clin (Barc); 1995 Jan; 104(1):11-4. PubMed ID: 7877347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbimazole and the autoimmune response in Graves' disease.
    McGregor AM; Petersen MM; McLachlan SM; Rooke P; Smith BR; Hall R
    N Engl J Med; 1980 Aug; 303(6):302-7. PubMed ID: 6247656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of thyroxine administration on serum thyrotropin receptor antibody and thyroglobulin levels in patients with Graves' hyperthyroidism during antithyroid drug therapy.
    Kuo SW; Huang WS; Hu CA; Liao WK; Fung TC; Wu SY
    Eur J Endocrinol; 1994 Aug; 131(2):125-30. PubMed ID: 8075781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term carbimazole intake does not affect success rate of radioactive 131Iodine in treatment of Graves' hyperthyroidism.
    El Refaei SM; Shawkat W
    Nucl Med Commun; 2008 Jul; 29(7):642-8. PubMed ID: 18528187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.
    Hashizume K; Ichikawa K; Sakurai A; Suzuki S; Takeda T; Kobayashi M; Miyamoto T; Arai M; Nagasawa T
    N Engl J Med; 1991 Apr; 324(14):947-53. PubMed ID: 1900575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remission with carbimazole therapy & assessment of T4 suppression test as an index of relapse in patients with Graves' disease in India.
    Goswami R; Bal CS; Gupta N; Kochupillai N
    Indian J Med Res; 1996 May; 103():272-7. PubMed ID: 8707364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of methimazole, with or without L-thyroxine, on remission rates in Graves' disease.
    Rittmaster RS; Abbott EC; Douglas R; Givner ML; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
    J Clin Endocrinol Metab; 1998 Mar; 83(3):814-8. PubMed ID: 9506733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.